Management of the patient with eosinophilic asthma: a new era begins

Jantina C de Groot, Anneke Ten Brinke, Elisabeth H D Bel, Jantina C de Groot, Anneke Ten Brinke, Elisabeth H D Bel

Abstract

Now that it is generally accepted that asthma is a heterogeneous condition, phenotyping of asthma patients has become a mandatory part of the diagnostic workup of all patients who do not respond satisfactorily to standard therapy with inhaled corticosteroids. Late-onset eosinophilic asthma is currently one of the most well-defined asthma phenotypes and seems to have a different underlying pathobiology to classical childhood-onset, allergic asthma. Patients with this phenotype can be identified in the clinic by typical symptoms (few allergies and dyspnoea on exertion), typical lung function abnormalities ("fixed" airflow obstruction, reduced forced vital capacity and increased residual volume), typical comorbidities (nasal polyposis) and a good response to systemic corticosteroids. The definitive diagnosis is based on evidence of eosinophilia in bronchial biopsies or induced sputum, which can be estimated with reasonable accuracy by eosinophilia in peripheral blood. Until recently, patients with eosinophilic asthma had a very poor quality of life and many suffered from frequent severe exacerbations or were dependent on oral corticosteroids. Now, for the first time, novel biologicals targeting the eosinophil have become available that have been shown to be able to provide full control of this type of refractory asthma, and to become a safe and efficacious substitute for oral corticosteroids.

Figures

FIGURE 1
FIGURE 1
Two different pathways lead to eosinophilic airway inflammation in asthma. In allergic asthma, dendritic cells present allergens to CD4+ T-cells, inducing T-helper (Th)2 cells, which produce interleukin (IL)-4, IL-5 and IL-13, and leading to IgE switching in B-cells, airway eosinophilia and mucous hypersecretion. In nonallergic eosinophilic asthma, air pollutants, microbes and glycolipids induce the release of epithelium-derived cytokines, including IL-33, IL-25 and thymic stromal lymphopoietin (TSLP), which activate innate lymphoid cells (ILCs) in an antigen-independent manner via their respective receptors (IL-17 receptor B (IL-17RB), ST2 and TSLP receptor (TSLPR)). Activated ILC2s produce high amounts of IL-5 and IL-13, leading to eosinophilia, mucus hypersecretion and airway hyperreactivity. CRTH2: chemoattractant receptor homologous molecule expressed on Th2 cells; ALX/FPR2: receptor for lipoxin A4; FcεRI: high-affinity receptor for IgE; GATA3: GATA-binding protein 3; PG: prostaglandin; ROR: retinoic acid receptor-related orphan receptor; NK: natural killer; MHC: major histocompatibility complex; TCR: T-cell receptor. Reproduced from [51] with permission from the publisher.
FIGURE 2
FIGURE 2
Effect of high dose triamcinolone on sputum eosinophils. Effect of treatment with intramuscular triamcinolone or placebo on sputum eosinophil percentages in 22 patients with eosinophilic asthma. Horizontal lines represent median values. Reproduced and modified from [87] with permission from the publisher.

References

    1. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804–813.
    1. Hekking PP, Bel EH. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol Pract 2014; 2: 671–680.
    1. Leynaert B, Sunyer J, Garcia-Esteban R, et al. . Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort. Thorax 2012; 67: 625–631.
    1. Moore WC, Bleecker ER, Curran-Everett D, et al. . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405–413.
    1. Simpson JL, Scott R, Boyle MJ, et al. . Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11: 54–61.
    1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716–725.
    1. Pavord ID. Eosinophilic phenotypes of airway disease. Ann Am Thorac Soc 2013; 10: Suppl., S143–S149.
    1. Amelink M, de Groot JC, de Nijs SB, et al. . Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol 2013; 132: 336–341.
    1. Lemiere C, Ernst P, Olivenstein R, et al. . Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006; 118: 1033–1039.
    1. Newby C, Agbetile J, Hargadon B, et al. . Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J Allergy Clin Immunol 2014; 134: 287–294.
    1. Ten Brinke A, Zwinderman AH, Sterk PJ, et al. . Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164: 744–748.
    1. Tran TN, Khatry DB, Ke X, et al. . High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol 2014; 113: 19–24.
    1. Ortega HG, Liu MC, Pavord ID, et al. . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–1207.
    1. Pavord ID, Korn S, Howarth P, et al. . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651–659.
    1. Bel EH, Wenzel SE, Thompson PJ, et al. . Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189–1197.
    1. Rackemann FM. Intrinsic Asthma. Bull NY Acad Med 1947; 23: 302–306.
    1. Lowell FC, Curry JJ, Schiller IW. A clinical and experimental study of isuprel in spontaneous and induced asthma. N Engl J Med 1948; 239: 45–51.
    1. Rackemann FM, Mallory TB.. Instrinsic asthma. Trans Am Clin Climatol Assoc 1941; 57: 60–73.
    1. Burrows B, Martinez FD, Halonen M, et al. . Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320: 271–277.
    1. Anderson HR, Gupta R, Strachan DP, et al. . 50 years of asthma: UK trends from 1955 to 2004. Thorax 2007; 62: 85–90.
    1. Grant EN, Wagner R, Weiss KB. Observations on emerging patterns of asthma in our society. J Allergy Clin Immunol 1999; 104: S1–S9.
    1. Holgate ST. The epidemic of allergy and asthma. Nature 1999; 402: Suppl., B2–B4.
    1. Peat JK, Li J. Reversing the trend: reducing the prevalence of asthma. J Allergy Clin Immunol 1999; 103: 1–10.
    1. Harvey AM, Howard JE, Winkenwerder WL, et al. . Observations on the effect of adrenocorticotrophic hormone (ACTH) on disseminated lupus erythematosus, drug hypersensitivity reactions, and chronic bronchial asthma. Trans Am Clin Climatol Assoc 1949; 61: 221–228.
    1. Chu EK, Drazen JM. Asthma: one hundred years of treatment and onward. Am J Respir Crit Care Med 2005; 171: 1202–1208.
    1. Godfrey S, Konig P. Beclomethasone aerosol in childhood asthma. Arch Dis Child 1973; 48: 665–670.
    1. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998; 12: 1209–1218.
    1. Ten Brinke A, Sterk PJ, Masclee AA, et al. . Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26: 812–818.
    1. Miranda C, Busacker A, Balzar S, et al. . Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: 101–108.
    1. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111: 913–921.
    1. Wenzel SE, Schwartz LB, Langmack EL, et al. . Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001–1008.
    1. Amelink M, de Nijs SB, de Groot JC, et al. . Three phenotypes of adult-onset asthma. Allergy 2013; 68: 674–680.
    1. Haldar P, Pavord ID, Shaw DE, et al. . Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218–224.
    1. Moore WC, Meyers DA, Wenzel SE, et al. . Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323.
    1. Siroux V, Basagana X, Boudier A, et al. . Identifying adult asthma phenotypes using a clustering approach. Eur Respir J 2011; 38: 310–317.
    1. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013; 131: 627–634.
    1. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012; 42: 650–658.
    1. Bousquet J, Chanez P, Lacoste JY, et al. . Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033–1039.
    1. Pin I, Freitag AP, O'Byrne PM, et al. . Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. Am Rev Respir Dis 1992; 145: 1265–1269.
    1. Durham SR, Craddock CF, Cookson WO, et al. . Increases in airway responsiveness to histamine precede allergen-induced late asthmatic responses. J Allergy Clin Immunol 1988; 82: 764–770.
    1. Aalbers R, Kauffman HF, Vrugt B, et al. . Allergen-induced recruitment of inflammatory cells in lavage 3 and 24 h after challenge in allergic asthmatic lungs. Chest 1993; 103: 1178–1184.
    1. Bacharier LB, Jabara H, Geha RS. Molecular mechanisms of immunoglobulin E regulation. Int Arch Allergy Immunol 1998; 115: 257–269.
    1. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009; 31: 425–437.
    1. Li-Weber M, Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol 2003; 3: 534–543.
    1. Zhu Z, Homer RJ, Wang Z, et al. . Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103: 779–788.
    1. Eum SY, Maghni K, Tolloczko B, et al. . IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway SM muscle. Am J Physiol Lung Cell Mol Physiol 2005; 288: L576–L584.
    1. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546–3556.
    1. Sewell WA, Mu HH. Dissociation of production of interleukin-4 and interleukin-5. Immunol Cell Biol 1996; 74: 274–277.
    1. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2015; 16: 45–56.
    1. Yu S, Kim HY, Chang YJ, et al. . Innate lymphoid cells and asthma. J Allergy Clin Immunol 2014; 133: 943–950.
    1. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19: 977–979.
    1. Bartemes KR, Kephart GM, Fox SJ, et al. . Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol 2014; 134: 671–678.
    1. Mjosberg JM, Trifari S, Crellin NK, et al. . Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12: 1055–1062.
    1. ten Brinke A, Grootendorst DC, Schmidt JT, et al. . Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002; 109: 621–626.
    1. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells – how did we miss them? Nat Rev Immunol 2013; 13: 75–87.
    1. Xue L, Salimi M, Panse I, et al. . Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 2014; 133: 1184–1194.
    1. Christianson CA, Goplen NP, Zafar I, et al. . Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J Allergy Clin Immunol 2015. [In press DOI: 10.1016/j.jaci.2014.11.037].
    1. Schleich F, Brusselle G, Louis R, et al. . Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014; 108: 1723–1732.
    1. Wenzel S, Ford L, Pearlman D, et al. . Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455–2466.
    1. Haldar P, Brightling CE, Hargadon B, et al. . Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973–984.
    1. Nair P, Pizzichini MM, Kjarsgaard M, et al. . Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985–993
    1. van Veen IH, Ten Brinke A, Gauw SA, et al. . Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009; 124: 615–617.
    1. Hekking PP, Wener RR, Amelink M, et al. . The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015; 135: 896–902.
    1. Dodge RR, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 1980; 122: 567–575.
    1. De Carvalho-Pinto RM, Cukier A, Angelini L, et al. . Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med 2012; 106: 47–56.
    1. Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy 2009; 39: 1145–1151.
    1. Yoo HS, Shin YS, Liu JN, et al. . Clinical significance of immunoglobulin E responses to staphylococcal superantigens in patients with aspirin-exacerbated respiratory disease. Int Arch Allergy Immunol 2013; 162: 340–345.
    1. Romagnoli M, Vachier I, Tarodo de la Fuente P, et al. . Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J 2002; 20: 1370–1377.
    1. Volbeda F, Broekema M, Lodewijk ME, et al. . Clinical control of asthma associates with measures of airway inflammation. Thorax 2013; 68: 19–24.
    1. Meijer RJ, Postma DS, Kauffman HF, et al. . Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32: 1096–1103.
    1. Wenzel S. Severe/fatal asthma. Chest 2003; 123: Suppl., 405S–410S.
    1. Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10: 292–300.
    1. Bumbacea D, Campbell D, Nguyen L, et al. . Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24: 122–128.
    1. van Veen IH, Ten Brinke A, Sterk PJ, et al. . Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008; 32: 344–349.
    1. Berry MA, Shaw DE, Green RH, et al. . The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35: 1175–1179.
    1. Jarvis D, Newson R, Lotvall J, et al. . Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy 2012; 67: 91–98.
    1. Samter M, Beers RF Jr. Concerning the nature of intolerance to aspirin. J Allergy 1967; 40: 281–293.
    1. Demoly P, Crampette L, Mondain M, et al. . Assessment of inflammation in noninfectious chronic maxillary sinusitis. J Allergy Clin Immunol 1994; 94: 95–108.
    1. Hamilos DL, Leung DY, Wood R, et al. . Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 1995; 96: 537–544.
    1. Harlin SL, Ansel DG, Lane SR, et al. . A clinical and pathologic study of chronic sinusitis: the role of the eosinophil. J Allergy Clin Immunol 1988; 81: 867–875.
    1. Moneret-Vautrin DA, Jankowski R, Bene MC, et al. . NARES: a model of inflammation caused by activated eosinophils? Rhinology 1992; 30: 161–168.
    1. Iino Y. Eosinophilic otitis media: a new middle ear disease entity. Curr Allergy Asthma Rep 2008; 8: 525–530.
    1. Iino Y, Nagamine H, Yabe T, et al. . Eosinophils are activated in middle ear mucosa and middle ear effusion of patients with intractable otitis media associated with bronchial asthma. Clin Exp Allergy 2001; 31: 1135–1143.
    1. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA–beclomethasone metered-dose inhaler compared with CFC–beclomethasone. Eur Respir J 1998; 12: 1346–1353.
    1. Richards J, Hirst P, Pitcairn G, et al. . Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14: 197–208.
    1. Hodgson D, Anderson J, Reynolds C, et al. . A randomised controlled trial of small particle inhaled steroids in refractory eosinophilic asthma (SPIRA). Thorax 2015; 70: 559–565.
    1. Ten Brinke A, Zwinderman AH, Sterk PJ, et al. . “Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170: 601–605.
    1. Green RH, Brightling CE, McKenna S, et al. . Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–1721.
    1. Jayaram L, Pizzichini MM, Cook RJ, et al. . Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483–494.
    1. Wenzel SE. Eosinophils in asthma – closing the loop or opening the door? N Engl J Med 2009; 360: 1026–1028.
    1. Veen JC, Smits HH, Ravensberg AJ, et al. . Impaired perception of dyspnea in patients with severe asthma. Relation to sputum eosinophils. Am J Respir Crit Care Med 1998; 158: 1134–1141.
    1. Abramson MJ, Perret JL, Dharmage SC, et al. . Distinguishing adult-onset asthma from COPD: a review and a new approach. Int J Chron Obstruct Pulmon Dis 2014; 9: 945–962.
    1. Suissa S, Ernst P, Benayoun S, et al. . Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336.
    1. Wu W, Bleecker E, Moore W, et al. . Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol 2014; 133: 1280–1288.
    1. Sweeney J, Brightling CE, Menzies-Gow A, et al. . Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax 2012; 67: 754–756.
    1. Ten Brinke A, de Lange C, Zwinderman AH, et al. . Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction. Am J Respir Crit Care Med 2001; 164: 749–753.
    1. Pin I, Gibson PG, Kolendowicz R, et al. . Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25–29.
    1. Korevaar DA, Westerhof GA, Wang J, et al. . Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med 2015; 3: 290–300.
    1. Westerhof GA, Korevaar DA, Amelink M, et al. . Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J 2015; [In press DOI: 10.1183/09031936.00012415].
    1. Katz LE, Gleich GJ, Hartley BF, et al. . Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014; 11: 531–536.
    1. Zhang XY, Simpson JL, Powell H, et al. . Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 2014; 44: 1137–1145.
    1. Alobid I, Cardelus S, Benitez P, et al. . Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis. Rhinology 2011; 49: 519–524.
    1. Fokkens WJ, Lund VJ, Mullol J, et al. . European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl 2012; 23: 1–298.
    1. Manson SC, Brown RE, Cerulli A, et al. . The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009; 103: 975–994.
    1. Noga O, Hanf G, Brachmann I, et al. . Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117: 1493–1499.
    1. Djukanovic R, Wilson SJ, Kraft M, et al. . Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170: 583–593.
    1. Massanari M, Milgrom H, Pollard S, et al. . Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma. Clin Pediatr (Phila) 2009; 48: 859–865.
    1. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131: 46–52.
    1. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19: 46–54.
    1. Corren J, Lemanske RF, Hanania NA, et al. . Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088–1098.
    1. Noonan M, Korenblat P, Mosesova S, et al. . Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013; 132: 567–574.
    1. Scheerens H, Arron JR, Zheng Y, et al. . The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014; 44: 38–46.
    1. Piper E, Brightling C, Niven R, et al. . A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41: 330–338.
    1. Slager RE, Otulana BA, Hawkins GA, et al. . IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol 2012; 130: 516–522.
    1. Menzies-Gow A, Flood-Page P, Sehmi R, et al. . Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111: 714–719.
    1. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007; 119: 1303–1310.
    1. Leckie MJ, ten Brinke A, Khan J, et al. . Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144–2148.
    1. Flood-Page P, Swenson C, Faiferman I, et al. . A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062–1071.
    1. Castro M, Zangrilli J, Wechsler ME, et al. . Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3: 355–366.
    1. Castro M, Mathur S, Hargreave F, et al. . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125–1132.
    1. Laviolette M, Gossage DL, Gauvreau G, et al. . Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086–1096.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe